HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 351.98% from the company’s previous close.

GANX has been the subject of several other reports. Weiss Ratings lowered shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. BTIG Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Finally, Roth Capital reissued a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $1.77 on Monday. The firm’s 50-day moving average price is $1.85 and its 200-day moving average price is $1.94. The company has a market capitalization of $77.24 million, a PE ratio of -3.54 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. Gain Therapeutics has a 1-year low of $1.53 and a 1-year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, equities analysts predict that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new position in Gain Therapeutics in the 2nd quarter valued at approximately $26,000. HB Wealth Management LLC bought a new stake in shares of Gain Therapeutics in the 2nd quarter worth $26,000. HighTower Advisors LLC bought a new stake in shares of Gain Therapeutics in the 2nd quarter worth $35,000. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter worth $39,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Gain Therapeutics in the fourth quarter worth $41,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.